 Trilostane is prepared from testosterone in a four-step synthesis.Trilostane was withdrawn from human use in the United States market in April 1994.It continued to be available in the United Kingdom for use in humans under the brand name Modrenal for the treatment of Cushing's disease and breast cancer in humans, but was eventually discontinued in this country as well.